A 36-week multicenter, randomized, double-blind, placebo-controlled, parallel-group, phase 3 clinical trial of sodium oligomannate for mild-to-moderate Alzheimer’s dementiaShifu Xiao, Raoli He, Shuzhen Wang et al.|Alzheimer s Research & Therapy|2021Cited by 200
Downregulation of Ripk1 and Nsf mediated by CRISPR-CasRx ameliorates stroke volume and neurological deficits after ischemia stroke in miceXincheng Song, Dantao Peng|Frontiers in Aging Neuroscience|2024Cited by 4